Showing results (1-10 of 151) with videos related to
Sort By:
Pageof 16
Current Opinion in Lipidology|May 15, 2007
Unravelling the functional significance of PCSK9Gilles LambertTrends in Endocrinology and Metabolism: TEM|February 21, 2006
PCSK9: a promising therapeutic target for dyslipidemias?Gilles Lambert, Michel Krempf, Philippe CostetCurrent Opinion in Lipidology|September 11, 2018
Key aspects of PCSK9 inhibition beyond LDL loweringStéphane Ramin-Mangata, Valentin Blanchard, Gilles LambertPresse Medicale (Paris, France : 1983)|June 20, 2006
[Physical activity in hypertension management]Xavier Chanudet, Gilles Lambert de Cremeur, Lionel BonnevieJournal of Clinical Lipidology|April 11, 2017
Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case seriesEstelle Nobecourt, Bertrand Cariou, Gilles Lambert, et al.European Heart Journal. Case Reports|April 26, 2019
Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case reportIlya Khantalin, Valentin Blanchard, Nicolas Viallet, et al.Clinical Biochemistry|April 1, 2014
Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteinsArjan J Kwakernaak, Gilles Lambert, Robin P F DullaartClinical Biochemistry|July 20, 2012
Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjectsArjan J Kwakernaak, Gilles Lambert, Robin P F DullaartCurrent Atherosclerosis Reports|December 5, 2023
HDL as a Treatment Target: Should We Abandon This Idea?Floran Begue, Marie Laurine Apalama, Gilles Lambert, et al.Pageof 16